Lepu Medical's net profit in the first half of the year: medical device business continues to grow and seek new AI+ medical layout
Lepu Medical recently disclosed the semi-annual report data showing that the company (including subsidiaries, the same below) realized operating income of 2,954,460,000 yuan, an increase of 35.37% over the same period of last year; realized operating profit of 996,172,400 yuan, an increase of 49.75% over the same period of last year; realized attributable to shareholders of listed companies The net profit was 890.75 million yuan, a year-on-year increase of 63.48%; the net cash flow from operating activities was 534,322,400 yuan, a year-on-year increase of 38.85%; the weighted average return on equity was 12.63%, an increase of 3.97 percentage points over the same period of the previous year.
In the first half of 2018, due to the wholly-owned acquisition of Australia's Viralytics Company by Merck, Lepu Medical disposed of 13.04% of the shares, achieving an investment income of RMB 205,064,400. Meanwhile, the subsidiary of the Netherlands, Comed BV, passed a section in a specific market. After the integration period, the strategic synergy effect did not meet expectations. After careful consideration, it was shut down and cleaned up, resulting in a one-time loss of approximately RMB 32 million. Excluding the above investment income and the loss of the subsidiary, the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is 670,198,000 yuan, an increase of 36.67%; the weighted average return on net assets after deducting non-recurring gains and losses is 10.45%. , an increase of 1.87 percentage points over the same period of the previous year, and the business performance continued to increase steadily.
In the first half of the year, the total assets of Lepu Medical were RMB 1,399,366,000, an increase of 9.38% compared with the beginning of the period; the net assets attributable to shareholders of listed companies was RMB 631,615,320, down 1.77% from the beginning of the period, mainly due to the acquisition of 45% of the minority shareholders of Xindonggang Pharmaceutical Co., Ltd. For the equity, the acquisition consideration is greater than the share of the net assets calculated according to the shareholding ratio, which is offset by the capital reserve of RMB 709.987 million.
In the first half of the year, the business of each segment of Lepu Medical continued its growth in the first quarter, and the overall development momentum was good. Among them, the medical device sector continued to grow, the pharmaceutical sector grew rapidly, and medical services, new medical services and other businesses steadily advanced. Among them, the medical device segment is still the sector with the largest weight of Lepu Medical. During the reporting period, the segment achieved operating income of RMB 1,396,232,500, a year-on-year increase of 15.56%, and a net profit of RMB 441,170,300, a year-on-year increase of 20.55%, maintaining a relatively fast growth trend. The growth rate of the main high-margin products in the medical device segment was above 20%. The company's strategic exit from the low-margin and difficult-to- pay medical product distribution business slightly lowered the overall revenue growth of the device segment.
1. Self-produced cardiovascular consumable products
The company's self-produced cardiovascular consumable products mainly include high-value consumable products such as stent system, pacemaker and occluder. During the reporting period, the company continued to optimize the variety structure of the stent products, further expanded its market share, and realized operating income of RMB 71,200,900, a year-on-year increase of 20.76%. Among them, the intravascular carrier-free drug (rapamycin) eluting stent system (Nano) operating income increased steadily year-on-year, accounting for 45% of the stent system sales structure. The higher growth rate of the stent system guarantees the continued growth of the medical device segment.
During the reporting period, the company continued to increase the marketing of dual-chamber pacemaker series products, and completed bidding work in Tibet and Hunan Province. The number of successful bidders has increased to 23, and has been included in the Beijing-Tianjin-Hebei regional alliance procurement catalogue. However, the bidding work in the core provinces has not yet started. At present, the clinical trial work of this product has progressed smoothly after the market launch, and has been completed in 27 provinces.
During the reporting period, the company's occluder series products achieved operating income of RMB 60,052,900, a year-on-year increase of 22.88%, and continued to maintain its leading position in the market.
During the reporting period, the company continued to promote the development and clinical registration of core device products. The fully degradable polymer matrix drug (rapamycin) eluting stent system (NeoVas) is currently under review and is expected to be registered for production within 2018; the left atrial appendage occluder and delivery device project has completed clinical implantation and The annual clinical follow-up work is currently undergoing the collation of follow-up data. It is expected to apply for registration in the fourth quarter of 2018. The medical device registration of the AI-ECG Platform, an automatic analysis and diagnosis system for electrocardiogram, has been accepted by the FDA and is now under registration review. The FDA has been registered in 2018; the drug-eluting balloon has been fully clinically enrolled, and clinical follow-up work is underway; the degradable occluder is still in clinical trials.
2, basic hospital interventional treatment and cardiovascular department cooperation business
In the first half of the year, the business realized equipment and consumables operating income of 271.876 million yuan, an increase of 1.81% over the same period of the previous year. The overall business maintained a stable development trend.
With the promotion and application of new medical angiography X-ray machines such as Vicor-CV400 in the middle and high-end medical institutions and the synergy of the financial leasing business, it provides a guarantee for the smooth development of the cooperation between the catheterization room and the cardiovascular department in the primary hospital. During the reporting period, Lepu Medical strategically withdrew from some of the relatively low-cost cooperative hospitals to intervene in the cath lab, and turned into a distribution model, which effectively achieved the overall control objectives of accelerating the withdrawal of funds, despite the new hospitals and reservations. The hospital's revenue still maintained high growth, but the overall operating income remained stable.
3. In vitro diagnostic products
The in vitro diagnostic business grew rapidly, achieving an operating income of RMB 159,934,000, a year-on-year increase of 23.45%.
Through the integration of in vitro diagnostics business, while giving full play to the advantages of various business areas, to achieve the overall effect of group platforms, in order to POCT and Thrombelastogram Pictured competitive products, biochemical and immunological focus areas to molecular diagnostics and mass spectrometry The industrial layout of the development priorities has played a positive synergistic effect. Lepu Diagnostics has quickly entered the market by adjusting its sales strategy with a focus on cardiovascular, myocardial, blood lipids and glucose metabolism. At the same time, with excellent product quality and perfect after-sales service, it has become a strategic supplier of Roche Diagnostics, and has achieved strong alliances, laying a solid foundation for the company in the field of biochemical diagnosis.
4, surgical products
In the first half of the year, surgical instruments such as staplers achieved operating income of RMB 129.971 million, a year-on-year increase of 41.75%, and a net profit of RMB 42.97 million, a year-on-year increase of 22.14%. Among them, the core products of the intracavity cutting stapler and its components series of products realized operating income of 58.686 million yuan, an increase of 142.53%, the performance has been greatly improved.
Through the optimization and upgrading of surgical products, the product quality and production cost are further improved. By expanding the market, optimizing sales channels, and strengthening academic promotion, the market share and brand influence of surgical products have been effectively improved, and the performance has been achieved. Rapid growth.
5, medical product agent distribution business
In the first half of the year, through continuous adjustment of the product structure of the agent distribution business, the expansion of high-margin products, and the reduction of low-margin products, the distribution of business products and agent business realized income of 137,745,800 yuan, a decrease of 2.80% over the same period of the previous year.
The medical service sector is an important part of the Lepu Medical Cardiovascular Health Platform. After the continuous deployment of the Lepu Cardiovascular Chronic Diseases Health Management Center, the Regional Cardiovascular Chronic Disease Consultation Health Management Center and the grassroots clinic (ie pharmacy clinic) and other three-level telemedicine system. In the first half of the year, Lepu Medical has signed nearly 400 pharmacy clinics. By June 2018, the number of patients receiving telemedicine services exceeded 280,000. The basic hospitals have cooperated with the catheter room to sign 242 contracts, covering 28 provinces and autonomous regions in the country. Among them, the grassroots hospitals that have been put into operation have cooperated with the catheter room to reach 166.
The medical services sector is a new business segment that Lepu Medical is cultivating. At this stage, the rapid growth of operating income and the increase in market share are the main purposes, which will cause short-term business losses. In the first half of the year, the medical service segment realized an operating income of 108,903,500 yuan, and the business had a total loss of 18,405,800 yuan.
In addition, Lepu Medical also deploys new medical formats in the areas of smart medical and artificial intelligence, financial services and strategic equity investment, exploring new products and new fields, and conducting forward-looking and diversified strategic layout to ensure healthy and sustainable development in the future.
Led Facial Mask,Led Light Facial Mask,Led Therapy Facial Mask,Led Facial Skin Care Mask
Shenzhen Jie Zhong Lian Investment Co., Ltd. , https://www.szmeizonscares.com